Rhythm Pharmaceuticals, Inc. (RYTM) stock
RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30249% above fair value
$109.86−2.30 (-2.05%)
Close on Nov 12, 2026Market cap $7.56BP/E –Yield –
Rhythm Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Rhythm Pharmaceuticals's enterprise value was $7.49B on Nov 11, 2026, against $6.97B a year earlier. Over the last 5 years it ranged from -$67.61M to $7.49B, with a median of $2.42B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $7.49B | +9.7% |
| 2025 | Dec 31, 2025 | $6.83B | +117.5% |
| 2024 | Dec 31, 2024 | $3.14B | +29.9% |
| 2023 | Dec 29, 2023 | $2.42B | +89.5% |
| 2022 | Dec 30, 2022 | $1.28B | +636.1% |
| 2021 | Dec 31, 2021 | $173.32M | -84.4% |
| 2020 | Dec 31, 2020 | $1.11B | +76.2% |
| 2019 | Dec 31, 2019 | $631.49M | -3.1% |
| 2018 | Dec 31, 2018 | $651.82M | +2999.5% |
| 2017 | Dec 29, 2017 | $21.03M | – |
See a number that looks wrong?